The harmful effects of private equity in the healthcare delivery system "deserves ongoing scrutiny and greater research," HHS said in a Jan. 15 report .
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...